One-Year Surgical Outcomes and Quality of Life after Minimally Invasive Sling Procedures for the Treatment of Female Stress Urinary Incontinence: TVT SECUR® vs. CureMesh® by Joo, Young Min et al.
Korean Journal of Urology
Ⓒ The Korean Urological Association, 2010 337 Korean J Urol 2010;51:337-343
www.kjurology.org
DOI:10.4111/kju.2010.51.5.337
Voiding Dysfunction
One-Year Surgical Outcomes and Quality of Life after Minimally 
Invasive Sling Procedures for the Treatment of Female Stress 
Urinary Incontinence: TVT SECUR
® vs. CureMesh
®
Young Min Joo, Jin Ho Choe, Ju Tae Seo
Department of Urology, Cheil General Hospital, Kwandong University College of Medicine, Seoul, Korea
Purpose: We compared the efficacy and safety of two minimally invasive sling proce-
dures used to treat female stress urinary incontinence (SUI), tension-free vaginal tape 
(TVT) SECUR
® and CureMesh
®, and assessed the 1-year surgical outcomes.
Materials and Methods: Sixty women with SUI were assigned to undergo either the 
TVT SECUR (n=38) or CureMesh (n=22) procedures between April 2007 and June 2008. 
Patients were monitored via outpatient visits at 1 month, 3 months, and 1 year after 
surgery. The efficacy of these procedures was evaluated by the cough test or by a urody-
namic study. At these postoperative visits, the patients also completed several ques-
tionnaires, including incontinence quality of life, patient’s perception of urgency se-
verity, the scored form of the Bristol Female Lower Urinary Tract Symptoms, visual 
analog scale, and questions about perceived benefit, satisfaction, and willingness to 
undergo the same operation again. The objective cure rate was defined as no leakage 
during the cough test with a full bladder. The subjective cure rate was evaluated by 
self-assessment of goal achievement performed 1 year postoperatively.
Results: The two groups were similar in preoperative characteristics and urodynamic 
parameters. The objective cure rates were similar between TVT SECUR and CureMesh 
(68.4% vs. 77.3%). All respondents reported improvement after surgery. There were 
no intra-operative complications.
Conclusions: Our results showed that the TVT SECUR and CureMesh procedures are 
both safe and simple to perform and have no significant differences in efficacy. 
Comparative studies with long-term follow-up are warranted to determine the true effi-
cacy of these procedures.
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INTRODUCTION
Stress urinary incontinence (SUI) accounts for over 80% of 
female urinary incontinence and consists of involuntary 
leakage of urine with effort, exertion, sneezing, coughing, 
laughing, exercising, or any maneuver that causes in-
creased intra-abdominal pressure [1,2]. In South Korea, 
about 21% of middle-aged women are known to have SUI 
that deteriorates their quality of life [3].
　Surgery is one of the most effective treatments for SUI. 
Currently, the tension-free vaginal tape (TVT) procedure, 
a modified sling procedure first described by Ulmsten et al 
in 1996, is the most widely used [4] and has a high cure rate 
of 80-100% [5,6] and long-term success rate of 78.9-95.2% 
[7-10]. However, the TVT procedure has reported complica-
tions that include bladder perforation, postoperative uri-
nary retention, retropubic hematoma, and pain [5,7]. To 
minimize some of these complications, such as bladder or 
intestinal perforation, the transobturator tape (TOT) pro-
cedure, a technique working through the obturator fora-
men, was developed by Delorme et al [11,12].
　Recently, a minimally invasive sling technique involv-
ing a single incision on the anterior vaginal wall was devel-
oped to reduce pelvic organ damage and pain. The TVT Korean J Urol 2010;51:337-343
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SECUR system (Gynecare, Ethicon, Somerville, NJ, USA) 
was first used in 2006 [13], and the MiniArc
TM single-in-
cision sling (American Medical System, Minnetonka, MN, 
USA) was introduced in 2007. Another domestic monofila-
ment polypropylene mesh similar to MiniArc called Cure-
Mesh (HueMedion, Namyangju, South Korea) has also 
been used. To date, however, there are few domestic reports 
related to these procedures. For this reason, we compared 
the efficacy and safety of two procedures (TVT SECUR sys-
tem and CureMesh) through a 1-year follow-up study.
MATERIALS AND METHODS
In this prospective, nonrandomized study, subjects were 
patients diagnosed with female SUI who underwent the 
TVT SECUR procedure (40 patients) or the CureMesh pro-
cedure (22 patients) from April 2007 to June 2008. Through 
preoperative physical examination and urodynamic stud-
ies, patients with pelvic organ prolapse, suspected in-
trinsic sphincter deficiency, or suspected urinary ob-
struction were excluded. A total of 60 patients, 38 patients 
in the TVT SECUR group and 22 patients in the CureMesh 
group, who were followed up for 1 year or longer were 
included. All operations were carried out under mask in-
halation anesthesia by a single surgeon. In cases in the TVT 
SECUR group, the “U position” or “Hammock position” was 
used. The inserter tip was oriented to 45° from the sagittal 
plane toward the ipsilateral shoulder in the “U position,” 
similar to the traditional TVT route. The inserter tip was 
oriented at an angle of 45° from the midline toward the is-
chiopubic ramus and the tip was approximately in the 3 and 
9 o’clock positions in the “Hammock position,” similar to the 
obturator foramen approach [13]. In cases in the CureMesh 
group, the tape was positioned similarly to the “Hammock 
position” approach. The Foley catheter was removed the 
morning of postoperative day 1. Timed voiding or clean in-
termittent self-catheterization (CIC), if necessary, were 
used in patients who failed to void, in those with a post-void 
residual (PVR) greater than 150 ml, or in those with blad-
der outlet obstruction symptoms.
　Preoperatively, all patients underwent history taking, 
pelvic examination, 3-day voiding diary, urinalysis, urine 
culture, Q-tip test, full bladder standing stress test, 1-hour 
pad test, and urodynamic studies including uroflowmetry. 
Patients also filled out several questionnaires, such as the 
incontinence quality of life (I-QoL), patient’s perception of 
urgency severity (PPUS), visual analogue scale (VAS) for 
incontinence, Self-assessment/Sandvik questions, and the 
scored form of the Bristol Female Lower Urinary Tract 
Symptoms questionnaire (BFLUTSSF), prior to the oper-
ation and 1 year after the operation. Uroflowmetry and 
PVR urine tests were carried out to assess the cure rate and 
the complication rate, respectively. Some patients’ ques-
tionnaires were completed by telephone interview. 
Questions on self-assessment of goal achievement and pa-
tient benefit, satisfaction, and willingness to have the oper-
ation again (BSW) were asked especially to evaluate the pa-
tients’ subjective satisfaction postoperatively. The full 
bladder standing stress test by coughing was carried out 
to assess the objective cure rate.
　The objective surgical outcomes were evaluated by the 
Stamey classification. Cure was defined as the absence of 
any episodes of involuntary urine leakage during stressful 
activities and the stress cough test. Improvement was de-
fined as a significant reduction in urine leakage, such that 
it did not require further treatment [14].
　Recurrence of urinary incontinence was confirmed by 
urine leakage in the standing stress test with a full bladder. 
Also, after showing the patients their pre-treatment goals, 
subjective satisfaction was rated as satisfactory with 
greater than 4 points or more in goal attainment scores, as 
unchanged with 3 points, and as dissatisfactory with 2 
points or less on the self-assessment of goal achievement 
questionnaire.
　Statistical analysis was performed with PC-SPSS ver-
sion 12.0 (SPSS, Inc., Chicago, IL, USA) using paired 
Student's t-test, chi-square test, and Wilcoxon rank sum 
test. A p-value of less than 0.05 was considered statistically 
significant.
RESULTS
The average follow-up period was 18.4±2.9 months for the 
TVT SECUR group and 17.8±1.8 months for the CureMesh 
group (p=0.086). There were no significant differences in 
preoperative clinical findings between the two groups 
(Table 1).
　One-year objective success rates were 86.8% in the TVT 
SECUR group (68.4% cured, 18.4% improved, and 13.2% 
failed) and 90.9% in the CureMesh group (77.3% cured, 
13.6% improved, and 9.1% failed). Patients’ subjective sat-
isfaction scores of the operation were 68.4% and 77.3% sat-
isfactory, 10.5% and 9.1% unchanged, and 21.1% and 
13.6% dissatisfactory, respectively, but showed no stat-
istical significance (Table 2).
　Between the two groups, the average operation time was 
shorter in the CureMesh group, and the duration of in-
dwelling Foley catheter use showed no difference (Table 3). 
However, there were three cases (7.9%) with a PVR of more 
than 150 ml on postoperative day 1 in the TVT SECUR 
group; two of those resolved with timed voiding only, and 
the other one recovered via timed voiding and CIC for 4 
days.
　Four (10.5%) cases of de novo urgency occurred in the 
TVT SECUR group and two (9.1%) in the CureMesh group; 
however, there was no statistical significance in the differ-
ence between the two groups (Table 3). Among them, four 
improved within 3 months following administration of an-
ti-cholinergics and two did not improve even with more 
than 12 months of medication. The two groups had no major 
complications such as intra-operative bladder perforation, 
hemorrhage requiring transfusion, or postoperative retro-
pubic hematoma. Complications such as vaginal erosion 
were not found at the 1-year postoperative physical exami-Korean J Urol 2010;51:337-343
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TABLE 1. Clinical characteristics of patients treated with the TVT SECUR and CureMesh procedures
TVT SECUR (n=38) CureMesh (n=22) p-value
Age (years) 52.0±7.6 50.4±6.9 0.421
Follow-up period (months) 18.4±2.9 17.8±1.8 0.086
No. of parity  2.2±0.9   2.1±0.5 0.535
Postmenopausal 21 (55.3) 11 (50.0) 0.455
Previous pelvic surgery 11 (28.9) 4 (18.2) 0.541
BMI (kg/m
2) 24.4±2.9 25.6±4.0 0.199
Positive stress test (%) 32 (84.2) 17 (77.3) 0.499
Q-tip test (＞30
o) 33 (86.8) 16 (72.7) 0.176
Pad test (g)  12.0±14.9     9.9±17.1 0.606
Preoperative storage symptoms
   Frequency (＞8/day) 23 (60.5) 17 (77.3) 0.260
   Nocturia (≥1/night) 8 (21.2) 8 (36.4) 0.159
   Urgency 28 (73.7) 13 (59.1) 0.350
   Urge incontinence 15 (39.5) 10 (45.5) 0.595
Preoperative symptom/QoL score
   Symptom 16.3±8.2 16.2±7.5 0.961
   QoL  4.8±1.2    4.5±0.9 0.241
Preoperative urodynamic parameters
   Detrusor overactivity 7 (18.4) 4 (18.2) 0.601
   Qmax (ml/s)  31.9±11.5  30.7±9.9 0.679
   Voided volume (ml) 366.4±85.8   368.9±101.0 0.917
   PVR (ml)    7.7±12.5 8.3±13.2 0.856
   Pdet at Qmax (cmH2O)  35.2±14.6 32.4±9.9 0.473
   MUCP (cmH2O)  72.2±25.2   81.4±24.6 0.171
   VLPP (cmH2O) 104.2±12.6 102.7±11.9 0.646
Values are given as Mean±SD or number (%), TVT: tension-free vaginal tape, BMI: body mass index, QoL: quality of life, Qmax: maximal 
flow rate, PVR: post void residual, MUCP: maximal urethral closure pressure, VLPP: Valsalva leak point pressure
TABLE 2. Comparison of clinical outcomes of patients treated 
with TVT SECUR and CureMesh
TVT SECUR 
(n=38)
CureMesh 
(n=22)
p-value
Objective cure rates
Cure 26 (68.4) 17 (77.3) 0.463
Improvement   7 (18.4) 3 (13.6) 0.632
Failure   5 (13.2) 2 (9.1) 0.636
Satisfaction
Satisfied 26 (68.4) 17 (77.3) 0.463
Tolerable   4 (10.5) 2 (9.1) 0.858
Fair   8 (21.1) 3 (13.6) 0.474
Values are given as number (%), TVT: tension-free vaginal tape
nation (Table 3). There were five cases (13.1%) of recurrence 
of SUI in the TVT SECUR group and two cases (9.1%) in 
the CureMesh group. All recurrences were cured by re-op-
eration with the TOT procedure on average 4.2 months af-
ter surgery.
　In the 1-year follow-up uroflowmetry, the maximum 
urine flow rate (Qmax) of the CureMesh group significantly 
decreased from 31.0 ml/s to 26.1 ml/s, but the values were 
within the normal range (Table 4). Urinary storage symp-
toms such as daytime frequency, nocturia, urgency, and 
urge incontinence were all significantly improved in the 
TVT SECUR group, and only nocturia and urgency symp-
toms were significantly improved in the CureMesh group 
(Table 4). Also, in both groups, postoperative questio-
nnaires, such as I-QoL, PPUS, VAS for incontinence, Self- 
assessment/Sandvik questions, and BFLUTSSF, showed 
significant improvements in all aspects (Table 5). In the 
questionnaire about the patient’s willingness to repeat the 
operation, 31 patients (93.9%) in the TVT SECUR group 
and 17 patients (85.0%) in the CureMesh group responded 
positively to undergoing surgery. For recommending sur-
gery, 31 patients (93.9%) and 20 patients (90.9%), re-
spectively, responded positively to willingness to recom-
mend the procedure to another person.
DISCUSSION
The tension-free mid-urethral sling procedure, the gold 
standard of treatment for female SUI, is based on the in-
tegral theory proposed by Petros and Ulmsten in 1993 [15]. 
The TVT procedure, introduced by Ulmsten et al in 1996, 
has spread worldwide as the first-generation sling proce-
dure, and it is still the most universally used owing to its 
high efficacy and safety [4,16]. However, in a large-scale 
study involving 1455 patients from 38 hospitals perform-
ing TVT procedures, major surgical complications such as Korean J Urol 2010;51:337-343
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TABLE 3. Comparison of the intraoperative and postoperative parameters of patients treated with TVT SECUR and CureMesh
TVT SECUR (n=38) CureMesh (n=22) p-value
Operation time (min)  5.3±1.3  3.8±1.1 ＜0.001
Total anesthesia duration (min) 25.7±6.0 25.2±6.1 0.784
Hospital stay after operation (hours)  31.2±15.8  34.6±14.4 0.418
Perioperative complications
Groin pain 1 (2.6) 0 NS
Vaginal wall penetration 0 0 NS
Bladder perforation 0 0 NS
Hb loss (g/dl)  1.13±0.89  1.45±0.53 0.134
Postoperative complications
Vaginal erosion 0 0 NS
Urethral erosion 0 0 NS
Paravesical hematoma 0 0 NS
Urinary infection 1 (2.6) 0 NS
Dyspareunia 0 0 NS
Postoperative voiding difficulty
PVR＞150 ml
a 3 (7.9) 0 (0) 0.188
Postoperative storage symptoms
b
Frequency (>8/day) 3 (7.9) 2 (9.1) 0.826
Nocturia (≥1/night) 2 (5.3) 4 (18.2) 0.093
Urgency 7 (18.4) 4 (18.2) 0.804
Urge incontinence 6 (15.8) 5 (22.7) 0.657
De novo urgency 4 (10.5) 2 (9.1) 0.908
Values are given as number (%), TVT: tension-free vaginal tape, NS: not significant, Hb: hemoglobin, PVR: post void residual. 
a: at 
first postoperative day, 
b: at one year after surgery
TABLE 4. Changes in uroflowmetry parameters and storage symptoms before and after surgery
TVT Secur (n=33) CureMesh (n=20)
Preoperative Postoperative p-value Preoperative Postoperative p-value
Uroflowmetry parameters
Qmax (m/s)  31.4±11.9 29.5±14.2 0.350 31.0±10.0 26.1±11.4 0.006
Voided volume (ml)  365.6±76.9 268.2±169.5 0.003 375.3±98.8 277.0±117.7 0.006
PVR (ml)   7.9±13.2 10.6±20.2 0.376   9.4±14.6   9.5±12.0 0.983
Storage symptoms
Frequency (times/day) 8.6±3.5 7.6±1.9 0.018 8.6±2.9 8.6±2.2 0.524
Nocturia (times/night) 0.8±1.0 0.3±0.5 0.003 1.0±1.1 0.5±0.8 0.019
Urgency 28 (73.7) 7 (18.4) ＜0.001 13 (59.1) 4 (18.2) 0.006
Urge incontinence 15 (39.5) 6 (15.8) 0.019 10 (45.5) 5 (22.7) 0.101
Values are given as Mean±SD or number (%), TVT: tension-free vaginal tape, Qmax: maximal flow rate, PVR: post void residual. 
Recurred patients were excepted in this data
bladder perforation, abdominal organ injuries, massive 
hemorrhage (＞200 ml), vascular injuries, nerve injuries, 
and hematoma were reported [17]. Some studies have re-
ported that this procedure has a higher rate of complica-
tions and a longer recovery period than do current colposus-
pension procedures [18,19]. The second-generation sling 
procedures were developed to reduce major complications 
such as bladder perforation and to eliminate the need for 
intra-operative cystoscopy. Delorme first described the 
TVT-obturator (TVT-O) procedure in 2001, which is per-
formed through the obturator foramen, and de Leval pre-
sented the inside-out form of the procedure in 2003 [11,12]. 
However, although complications such as adjacent organ 
injuries, obturator nerve injuries, and pain are decreased 
for the TVT-O and the TOT procedures, such complications 
are still reported [20]. The TVT SECUR procedure, first in-
troduced in 2006, is minimally invasive compared with pre-
vious procedures and was developed to minimize pelvic or-
gan damage or vascular injuries because it does not involve 
needle penetration of the retropubic space or the obturator 
foramen. The minimally invasive, single-incision sling op-
eration, MiniArc-Minisling (similar to CureMesh
®) was in-
troduced in 2007 as a third-generation sling procedure, 
along with the TVT SECUR procedure. Both tips of the tape Korean J Urol 2010;51:337-343
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are self-fixating, and the procedures can be performed with 
a single incision on the anterior vaginal wall. However, sev-
eral complications have been reported, such as unintended 
tape removal at the time of inserter removal, vaginal wall 
perforation, or tape extrusion, but these have been decreas-
ing in frequency with increasing experience with the proce-
dures [21]. In our study, there were no complications other 
than two cases of inguinal pain and postoperative urinary 
tract infection.
　Currently, there are few studies on the efficacy of mini-
mally invasive, single-incision sling procedures. Examining 
short-term follow-up results (an average of 5-10 weeks), 
seven abstracts reported in the 2007 International 
Urogynecology Association (IUGA) on the TVT SECUR 
procedure showed a mean objective cure rate of 80.3% 
(range, 69-88%) with a mean objective recurrence rate of 
19.7% (range, 3-31%), with low rates of complications [13]. 
In addition, a 1-year follow-up study of the TVT SECUR 
procedure by telephone interview reported higher ob-
jective cure rates in the last 46 subjects (93.5%) than in the 
first 44 subjects (88.6%) [21]. Another 1-year study re-
ported an objective cure rate of 78% and a subjective cure 
rate of 81% after the TVT SECUR procedure [22]. Among 
the 107 patients who received TVT SECUR procedures, 
71% were cured and 14% were improved after 15 months 
[23]. In addition, 83.1% and 77.6% of 97 patients who re-
ceived MiniArc-Sling procedures showed no urine leakage 
in a cough provocative test at 6 weeks and 12 months after 
surgery, respectively, with significant improvements in 
69.1% of the patients’ quality of life [24]. According to a com-
parative study of the TVT SECUR and MiniArc-Sling pro-
cedures, the objective cure rate was 80.4% and 90.2%, re-
spectively, but the average follow-up period differed at 11 
months and 3.5 months for each group, respectively [25]. 
In our study, the cure rates for the TVT SECUR group and 
the CureMesh group were 68.4% and 77.3%, respectively, 
and improvements in symptoms were 18.4% and 13.6%, re-
spectively, showing similar results to previous studies and 
no significant differences between the two groups. All pa-
tients with recurrence were operated on in the initial phase 
and the recurrence was thought to be due to loosening of 
the fastening of the tape during inserter removal, although 
the tape was not removed with the inserter. A decrease in 
the urine flow rate in the uroflowmetry test in the Cure-
Mesh group was probably the result of hard fastening of the 
tape during the procedure, based on our experiences of past 
patient recurrences. Therefore, it was suggested that these 
procedures have a certain learning curve. Furthermore, in 
the CureMesh group, the average operation time was 
shorter than in the TVT SECUR group. Among the two min-
imally invasive sling procedures, our primary experience 
was with the TVT SECUR procedure, and our experience 
with the CureMesh procedure came later. This consecutive 
experience seems to reemphasize the importance of the 
learning curve.
　Acute urinary retention, one of the most common compli-
cations that occur after SUI procedures, is known to occur 
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in 2.3-10.0% of patients after TVT procedures [26]. Urinary 
retention is reported to occur in 0.9-8.0% after the TVT 
SECUR and MiniArc-MiniSling procedures [13,16,21-24]. 
In our study, uroflowmetry was performed on patients who 
complained of voiding difficulty after surgery, and there 
were 3 cases (5%) with voiding difficulty, which was defined 
as less than 15 m/s of maximal urine flow rate or a PVR of 
more than 150 ml of residual urine.
　The occurrence of de novo urgency after the TVT SECUR 
and MiniArc procedures has been reported at various rates, 
ranging from 5.6% to 36.8% [13,22-24]. We also observed 
de novo urgency in 10% of the patients in this study, but 
most improved with the administration of anticholiner-
gics. In addition, symptoms such as frequency, urgency, 
and urge incontinence after midurethral sling procedures 
in female SUI patients with overactive bladder accom-
panied by detrusor overactivity improved in 23.5-63.1% of 
patients [27-29]. In our study, postoperative symptoms 
such as daytime frequency, nocturia, urgency, and urge in-
continence were improved in 56.0-73.2% of the patients.
　It is important that surgical outcomes be evaluated ac-
cording to patient expectations and satisfaction. Recently, 
research in the field of SUI surgery reflects a similar trend 
of using patient expectations, goal selection and achieve-
ment, and QoL measures in determining surgical out-
comes. Significant improvement was reported on the Inter-
national Consultation on Incontinence Short Form (ICIQ- 
SF) and the Women Irritative Prostate Symptoms Score 
(W-IPSS) after the TVT SECUR procedure [21]. However, 
some investigators have reported that there was no change 
in the ICIQ-SF in the 3-month short-term follow-up of pa-
tients who underwent the TVT SECUR and MiniArc- 
Minisling procedures [24]. In our study, not all patients 
completed the questionnaires, but the I-QoL, PPUS, VAS, 
Self-assessment/Sandvik questions, and BFLUTSSF all 
showed significant improvements at 1 year after surgery. 
Also, the patients’ subjective satisfaction after reviewing 
the treatment goals made before treatment was relatively 
low at about 68.4% and 77.3% for the TVT SECUR group 
and the CureMesh group, respectively. The relatively low 
figure can probably be attributed to the fact that the pa-
tients had set treatment goals related to urine storage 
symptoms, such as frequency, urgency, and nocturia, that 
would not necessarily be reduced by these procedures. 
Therefore, it is necessary to make patients aware of the 
range of symptoms treatable by a given procedure by pre-
cisely explaining the nature of the disease and the potential 
outcomes of surgery. On the other hand, the BSW survey 
showed that 93.9% and 85.0% of patients would be willing 
to undergo surgery again, and 93.9% and 90.9% of patients 
would recommend surgery to others for the TVT SECUR 
and CureMesh procedures, respectively. These high fig-
ures reflect a high satisfaction rating in these patients.
CONCLUSIONS
In a 1-year follow-up comparison, the two minimally in-
vasive sling procedures, TVT SECUR and CureMesh, 
showed no significant differences in efficacy or safety. Our 
findings demonstrate that these procedures are safe, have 
shorter operation times, and are more convenient than con-
ventional procedures. Although these procedures have a 
lower cure rate than do current TVT or TOT procedures, 
efficacy can be improved with increasing proficiency of the 
surgeon. Long-term follow-up studies, including com-
parative studies with current procedures, are required to 
define efficacy.
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